Efficacy of karelizumab in combination with chemotherapy in advanced colorectal cancer and changes in tumor markers

XIE Ya-rong; YU Xiao-ping; WANG Bo; GUO Wei; WANG Xiao-ling

doi:10.3969/j.issn.1672-8157.2023.05.009

Abstract：Objective:To investigate the efficacy of programmed cell death molecule 1(PD-1)/PD-1 ligand(PD-L1)inhibitor Carelizumab combined with capecitabine and oxaliplatin in the treatment of advanced colorectal cancer.Methods:A total of 107 patients with advanced colorectal cancer recieving corresponding treatment regimens in our hospital were enrolled in this trial and randomized into two groups.The 54 patients in the control group were treated with capecitabine combined with oxaliplatin and 53 patients in the observation group with addition of arolizumab on the basis of the control.The treatment efficacy and adverse reactions as well as the serum levels of vascular endothelial growth factor(VEGF),carbohydrate antigen 19-9(CA19-9),carcinoembryonic antigen(CEA),and alpha fetoprotein(AFP)before and after treatment were compared between the 2 groups.Results:After treatment,the total effective rate and the specific disease control rate(DCR)were signicantly higher in the observation group(45.28% and 71.70%,respectively)than in the control(25.93%and 38.89%,respectively)(χ2 = 4.38,4.25,P = 0.036,0.039).The serum levels of specific concentrations of CA19-9,VEGF,AFP and CEA were significantly lowere in the observation group[280.21±11.67)ng·L-1,(51.52±8.22)U·mL-1,(7.49±0.98)ng·mL-1,(21.37±3.19)ng·mL-1]than in the control[(310.37±12.83)ng·L-1,(60.28±7.83)U·ml-1,(11.33±1.72)ng·mL-1,(28.51±4.28)ng·mL-1](t = 12.66,5.62,14.12,9.74,P<0.05).Conclusion:The combination of oxaliplatin and capecitabine with calerizumab in the treatment of advanced colorectal cancer patients has a good therapeutic efficacy and can be widely promoted in clinical practice.